Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment

Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience

“…Given its longer half-life as compared to endogenous luteinizing hormone (LH), hCG induces a prolonged luteotropic effect, potentiating the recruitment of multiples follicles and resulting in supraphysiologic E2 levels [19,20]. Recent data suggests the risk of OHSS may be reduced by utilizing GnRH agonist triggers [21,22].…”

No Association Between the Microsatellite Polymorphism (TTTTA) n in the Promoter of the CYP11A Gene and Ovarian Hyperstimulation Syndrome

“…Therefore, effective prognostic criteria for OHSS are still lacking. Our research was based on the observation that women with biochemical marker-based diagnosis of polycystic ovary syndrome (BM-PCOS) (1,4,6) as well as those with ultrasonic evidence of polycystic ovaries (US-PCOS), are at higher risk of OHSS. Moreover, the clinical and biochemical picture of OHSS are similar in both groups of patients (7).…”

Comparison of cryopreservation outcome following intracytoplasmic sperm injection and conventional in vitro fertilization

“…The ability to cryopreserve these supernumerary embryos and obtain viable pregnancies after thawing and embryo transfer (ET) served as an excellent solution to the problem of surplus embryos and increased the overall pregnancy rate from one oocyte retrieval attempt (2,3). Cryopreservation of embryos has additional advantages as it may be used in cases in which ovarian hyperstimulation syndrome is anticipated to occur and fresh ET is not recommended (4). In addition, although pregnancy rate for frozen-thawed embryos is somewhat lower than for fresh ET, the expenses for such ET cycles is far below the total cost incurred by a repeat fresh cycle.…”